The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) hosted its 2024 Global Congress in Barcelona, continuing its tradition of presenting high-quality data and fostering insightful discussions. Although the event has rebranded from ECCMID to ESCMID Global, the level of scientific excellence and engaging exchanges remained unchanged, attracting top-tier researchers and clinicians from around the world. Here are some notable highlights from the many vaccine abstracts topics being presented:
V116 pneumococcal vaccine shows promise
Encouraging results from the phase III STRIDE-10 trial evaluating V116, a 21-valent pneumococcal conjugate vaccine showed that V116 elicited immune responses non-inferior to the 23-valent PPSV23 for 12 common serotypes. The trial involved adults aged 50 and older who had not previously received a pneumococcal vaccine. Additionally, V116 demonstrated superior immune responses for nine unique serotypes compared to PPSV23. The safety profile of V116 was comparable to PPSV23, making it a promising candidate for adult pneumococcal vaccination.
Abstract details: A Phase 3, randomised trial investigating the safety, tolerability and immunogenicity of V116, an investigational adult-specific pneumococcal conjugate vaccine, compared with PPSV23, in adults ≥50 years of age (STRIDE-10). Presented on Monday 29th April. Abstract number 01000
Shingrix shows decade-long efficacy against shingles in phase III trial
Results from the ZOSTER-049 long-term follow-up phase III trial demonstrated that Shingrix (Recombinant Zoster Vaccine or RZV) maintains high efficacy against shingles for over a decade in adults over 50. The trial data showed 79.7% vaccine efficacy (VE) from year six to year 11, and 82.0% VE at year 11 for adults aged 50 and over. Additionally, for adults aged 70 and over, VE was 73.1% from six to 11 years post-vaccination. The study continues to evaluate long-term data for potential revaccination needs.
Abstract details: Adjuvanted recombinant zoster vaccine (RZV) is the first vaccine to provide durable protection against herpes zoster (HZ) in all age ranges ≥50 years: final analysis of efficacy and safety after 11 years (Y) of follow-up.Â
New malaria vaccine shows 64% efficacy maintained for 4 years in children
Researchers from Oxford University reported a significant breakthrough with the R21/Matrix-M malaria vaccine. In a phase IIb study in Nanoro, Burkina Faso, the vaccine maintained high efficacy in children aged 5–17 months over four years, showing 64% overall efficacy and 71% against the first malaria episode. This vaccine, developed with the Serum Institute of India and Novavax’s Matrix-M adjuvant, significantly outperforms the RTS, S/AS01 vaccine, which has only 36.3% efficacy. Over 25 million doses of R21/Matrix-M are ready for imminent rollout
Abstract details: Efficacy of R21/Matrix-Mâ„¢ in a phase IIb trial in children is maintained in Burkina Faso over four years. Presented on Sunday 28th April. Abstract number 00686
Study confirms safety and efficacy of dose-sparing mpox vaccine
A dose-sparing intradermal monkey pox (mpox) vaccination regimen was found to be safe and produced an antibody response comparable to the standard regimen at six weeks, two weeks post-second dose. These finding suggest the effectiveness of dose-sparing strategies during the 2022 US mpox outbreak. The study involved 225 adults aged 18-50 who were randomized to receive either the standard MVA-BN vaccine, one-fifth, or one-tenth of the standard dose, administered intradermally. Two weeks after the second dose, antibody levels in the one-fifth dose group matched those of the standard dose group, though they were lower by day 57. The one-tenth dose group had consistently lower antibody levels. Most adverse events were mild and similar across all groups, with no serious vaccine-related events reported.
Abstract details: Safety and Immunogenicity of Fractional Doses of Modified Vaccinia Ankara-Bavarian Nordic. Presented on Saturday, April 27, 2024
Disclosures: This article was created by the touchINFECTIOUS DISEASES team utilizing AI as an editorial tool (ChatGPT (GPT-4o) [Large language model]. https://chat.openai.com/chat.) The content was developed and edited by human editors. No funding was received in the publication of this article.
